To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Biotec Pharmacon receives promising interim results from animal study
27-01-2011: Biotec Pharmacon ASA has received an interim data report from the second animal study in diabetic mice. The results confirm the finding from the first study showing that a 2% aqueous solution of SBG has good wound healing capability. An important goal with the second study was to investigate different concentrations of SBG, and SBG in combination with an additional gel agent. Preliminary stability data has indicated that a mixed formulation would have increased stability as compared to a pure 2% aqueous solution of SBG. Also, different commercial hydrogels typically used in wound healing was included.
The results showed that SBG successfully can be mixed with different gel agents, and results also indicate that such mix improves the wound healing capability of the product. The best results were obtained with a combination of 2% SBG and carboxymethylcellulose (CMC), the latter being used in several of the commercial wound treatment hydrogels on the market, like Intrasite from Smith & Nephew and in the wound healing drug Regranex. This combination product of SBG and CMC induced statistically significant improved wound healing from day 12 and onwards throughout the study (day 24) only paralleled by the positive control. The results also confirm that such a SBG based product performs better than the other commonly used hydrogels containing CMC tested and also methylcellulose that was the placebo of the clinical studies.
As earlier reported, it was observed that a pure 2% aqueous solution of SBG when stored in aluminum tubes or polyethylene ampoules, were very sensitive to accelerated storage conditions as seen by early fragmentation of the gel. These two container types were accordingly chosen for the ongoing stability program to secure rapid progress in testing the new formulations. Preliminary data from the accelerated stability studies have so far indicated that the stability of SBG can be significantly improved. Either by increasing the concentration of SBG alone above 2% in water, resulting in a more solid gel, or by mixing SBG with an additional gel agent like CMC.
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Fighting listeria and other food-borne illnesses with nanobiotechnology
- 3Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 4Using human brain cells to make mice smarter
- 5Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 6Vivacta Initiates Development of Point of Care Test for Vitamin D
- 7A light switch inside the brain
- 8Researchers divide enzyme to conquer genetic puzzle
- 9New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 10Nomad Bioscience: new plant biotechnology company founded to focus on biomaterials and biopharmaceuticals
- Malvern Instruments announces global agreement with Proveris Scientific
- Analytik Jena to develop products for sepsis diagnostics
- analytica Vietnam 2013 – Platform for innovations
- Promega and BASF develop alternative method on identifying allergenic substances
- Prosensa receives rare disease 'Company Award' from EURORDIS
- More than 97% of Pronova’s shareholders accept BASF’s offer for Pronova BioPharma
- Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in acute myeloid leukaemia
- Clavis Pharma completes patient recruitment in Phase III study with elacytarabine in patients with acute myeloid leukaemia
- Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer
- Algeta initiates new R&D program to investigate a Targeted Thorium Conjugate (TTC) against hematological cancers